Thursday, December 31, 2020
My Sampandhi (Daughter in law father) KMS H sir got a cake with Marks of my profession and compuled to celebrate my birthday day for the first time in my 63rd year on 1.1.21 with my wife and grand children. Please wish me for a healthy life with many more laurels in this year - M.A.Aleem Trichy 1.1.21
Wednesday, December 30, 2020
Monday, December 28, 2020
COVID year of 2020 in Trichy - M.A.Aleem Neurologist #Trichy #Tamilnadu #India
COVID year of 2020 in Trichy
Trichy has recorded the first COVID-19 case in March 27,2020. The first COVID-19 related death was reported in June 3,2020.
In this COVID-19 Pandemic year 2020 Trichy has celebrated the Ramzan , Bakrid, Diwali, Christmas and Vaikunta Ekadasi including Paramapada vasal opening without any minor or major Outbreak of news cases of COVID-19. Thank God , people and the administrators of Trichy city and Trichy District for their support by all means to prevent the new COVID-19 Outbreak.
As of now on 52nd week of this Pandemic Trichy has recorded very low death rate of 1.22% and the total confirmed COVID-19 cases were 14,070 on Saturday (26.12.20).
There is a steady declining in the number of new COVID-19 cases and Hospital admissions. These are the good signs of COVID-19 control in the Trichy city and in the district.
Now our district is getting ready by requesting the Medical institutions and hospitals to upload the beneficiaries in COVID-19 vaccination portal.
- M.A.Aleem
Trichy
Saturday, December 26, 2020
In 52nd week of the COVID-19 Pandemic, world is preparing to face many challenges coming out of the newer COVID-19 variant and vaccination - M.A.Aleem BMJ 2020;371:m4850
BMJ British Medical Journal
Editor's Choice
Inspirations and silver linings in a pandemic year
BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4850 (Published 17 December 2020)
Cite this as: BMJ 2020;371:m4850
Re: Inspirations and silver linings in a pandemic year
Dear Editor
In 52nd week of the COVID-19 Pandemic, world is preparing to face many challenges coming out of the newer COVID-19 variant and vaccination
On 14 December 2020, authorities of the United Kingdom (UK) reported to WHO that a new SARS-CoV-2 (COVID-19) variant was identified through viral genomic sequencing.
Earlier Analysis indicates that the variant may spread more readily between people. Investigations are ongoing to determine if this variant is associated with any changes in the severity of symptoms, antibody response or vaccine efficacy.
Preliminary reports by the UK are that this variant is more transmissible than previous circulating viruses, with an estimated increase of between 40% and 70% in transmissibility (adding 0.4 to the basic reproduction number R0, bringing it to a range of 1.5 to 1.7).
Other than UK the new COVID-19 variant has been identified in several countries including Australia, Denmark, Italy, Iceland South Africa Nigeria and in
Netherlands.
The new COVID-19 strain is not detected in India as of on 25.12.2020.
India has noted several mutations in the novel coronavirus since March, out of which one was a super-spreader but it died on its own, said a top official from the Institute of Genomics and Integrative Biology (IGIB).
World has also facing a few challenges towards vaccination for COVID-19.
As positive results emerge at last with vaccination against COVID-19 , researchers must help the world to address the vaccine hesitancy, supply logistics and pricing to vaccinate every one in developed, developing and in underdeveloped countries
Common side effects on the arm where you got the shot include pain and swelling. You could also experience fever, chills, tiredness and headache. Some time a few allergic reactions has also been reported in a few with COVID-19 vaccination
Scientists say there’s no evidence that vaccines currently being deployed in the UK - made by Pfizer and BioNtech - or other COVID-19 shots in development will not protect against this new COVID-19 variant .
Competing interests: No competing interests
25 December 2020
M.A. Aleem
Emeritus Professor of Neurology * Visiting Specialist in Neurology ** Consultant Neurologist ***
The Tamilnadu Dr.M.G.R. Medical University * Dhanalakshami Srinivasan Medical College ** ABC Hospital ***
Chennai 600032* Perambalure 621212** Trichy 620018*** Tamilnadu India
@drmaaleem
Friday, December 25, 2020
Thursday, December 24, 2020
Biodata 2 IAN M.A.Aleem 2020
BIODATA 2
1. Name: M.A.Aleem
2. IAN Membership Number: LM-431
3.Please outline your research achievements:(Maximum 150 words)
I am having the research experience from 1997 to till date as a DM Post graduate student , as an Asst. Professor, Professor and as Emeritus Professor of Neurology. I have 44 Publications and 47 presentations of my research works in my credit. As a DM Post graduate M.A .ALEEM’S is research work at Madurai Medical College, Madurai (MMC) has published 11 research papers and it has 23 citations (https://www.researchgate.net/scientific-contributions/5855891_M_A_Aleem).As an Assistant Professor of neurology my research works were accepted by the World Federation of Neurology and I have presented my papers on 1.Seizure related injuries in rural epileptic women from in southern India in the World Congress of Neurology (WCN) 2001 London. 2.Iatrogenic Seizures – A clinical study from southern India in WCN 2001London.3.Circardian onset of stroke in young rural southern Indian population in WCN 2005Sydney 4.Study of psychogenic non epileptic Seizure in southern Indian rural population at WCN 2009 at Bangkok in Thailand. 5.Diffusion MR imaging in status epileptics – Reversibility a study from southern India at WCN 2015 Santiago Chile. All this above Presentation are Published in journal of Neurological science in above in that years as abstract. My research works was accepted by the International League Against Epilepsy and I have presented the paper on Cerebral calcification and epilepsy in rural population at 25thInternational Epilepsy Congress(IEC) 2003 Lisbon Portugal and a paper on southern Indian study on Iatrogenic seizure in 26th IEC 2005 Paris. Both were published as abstract in that year Epilepsia Journal. I have also presented my neurological research work in IANCON, and Neurocon.I have grant from Government of Tamilnadu state research committee to do the research work oncircadian rythem and stroke in southern Indian rural population for one year in 2004.I am a guide for Neurology research work with EEG & fMRI at Department of instrumentation and control. Engineering at National institute of Technology Trichy for PhD scholar from 2013 to 2016.
4.Please outline your contribution to the Indian Academy of Neurology:(Maximum 150 words)
I am a Life member in IAN since 1999 (L M 431).Served in IAN as a National Executive Committee member (2002 – 2009). I was appointed by IAN as organising Secretary to conduct the 2010IANCON for first thetime in 2nd tier city in Trichy As per IAN Instruction I have organised a preconference workshop at during IANCON 2010at Trichy. I am also served as member in the organising committee of IANCON - 2010Madurai and IANCON 2003 VIZAK and IANCON 2004 Nagpur .I have taken part in all IAN instructed Indian National Brain week activities, worldBrain day activities and other Neurological awareness activities.I have contributed articles for Reviews in Neurology on Myasthenic syndrome and on cerebral malaria in 2000 IANCON, and an Hypertension management in stroke in 2003 IANCON.I have chaired sessions and presented papers in IANCON many times. I have Published two Review articles on epilepsy in elderly and published papers in Annales of Indian academy of Neurology.I have undergone specialised training in Epilepsy as an IAN Sponsored candidate for 3 months at University College of London Queen's squire Neurology hospital in 2001IAN helped me to create an award for the Basic science research works with my contribution of Rupees 20 Lakhs to IAN in 2018.I am also served as Tamilnadu Pondicherry Association of Neurologist as vice-president,President Elect and as President for the year 2017 -18 and Now I am The past president of TAN.
5.Please outline your other significant contribution: (Maximum 150 words)
Prof Dr. Aleem has created and established the department of neurology at KAPV GOVT medical college and MGM GOVT hospital Trichy. He had a role in starting the DM Neurology higher specialty. Course at Thirunelveli Govt medical college in 2007. He has published 11 books in regional language on Neurology topics to create awareness among people. He is the examiner in the Tamilnadu Dr. MGR medical University. At present he is the president for Trichy Neuro club and Secretary for Neurologist association of Tiruchirappalli. He is the founder of NAT at Trichy 2017.He is a also instrumental in bringing the International Epilepsy Day by ILAE/IBE in 2015.Prof Dr. M.A. Aleem is conferred with best doctor award in the field of neurology by the Tamilnadu Dr. MGR Medical University in 2012.He had junior travelling fellowship award from WFN to attend WCN 2001 at London. He had congress attendee award from ILAE to attend 25th IEC at Lisbon. He had travelling bursary award from ILAE to attend 6th AOEC at Malaysia in 2006. He had commendation certificate from Trichy District collector for this Neurological Health care services for the year. 2005, 2006, 2014 – 2015, 2015 – 2016, 2016 – 2017.Prof Dr. Aleem had Republic day Best Doctor award for his contribution to rural Neurological awareness activity from Trichy collector in 2010. He had best administrator award from the Trichy district collect in 2013.He also had Dr. Banumathy Muruganathan award for the excellence in medical publication in Tamil by Tamilnadu IMA in 2008.He was nominated as Epilepsy purple day Ambassador in 2012 by EANS Newyork.He was nominated as Trichy district welfare fund committee life member by district collector and Truchy DWFC committee from 2017. He is also an advisor to phd students at NITT Trichy in the Instrumentation Engineering department.Dr Aleem was awarded 1st prize for his suggestions of Trichy SMART CITY by the Tiruchirappalli city Corporation in 2015Dr Aleem was awarded for his our Ptime Minister Modi ' s SWACHH BHARAT activities by Tiruchirappalli district collector in 2017.He is awarded with KALAM Award for Quality of life improvement by South Zone Board if Continuing Education Ozone on 18.11.2018.He has the research experience of more than 20 years in his carrier.ProfDr.M.A.Aleem has the Appointed as Emeritus Professor From Trichy Neurology Field at the Tamilnadu Dr. M.G.R. Medical University in 2018.Dr.Aleem is appointed as Trustee to age old Natharvali Dargah by Wakf Board of Government of Tamilnadu India for three years from 2.11.2018Dr M.A.Aleem 1st Neurologist appointed as Advisory Committee Member for the Tiruchirappalli International Airport by Airport Authority of India Director Tiruchirappalli International Airport on 10.12.2018.Dr. M.A.Aleem first Neurologist Trichy Tamilnadu is Nominated as Brand Ambassador for Swachh Bharat Mission by The Tiruchirappalli City Corporation of Goverment of Tamilnadu India at 70th Republic day on 26.1.2019
1. Name: M.A.Aleem
2. IAN Membership Number: LM-431
3.Please outline your research achievements:(Maximum 150 words)
I am having the research experience from 1997 to till date as a DM Post graduate student , as an Asst. Professor, Professor and as Emeritus Professor of Neurology. I have 44 Publications and 47 presentations of my research works in my credit. As a DM Post graduate M.A .ALEEM’S is research work at Madurai Medical College, Madurai (MMC) has published 11 research papers and it has 23 citations (https://www.researchgate.net/scientific-contributions/5855891_M_A_Aleem).As an Assistant Professor of neurology my research works were accepted by the World Federation of Neurology and I have presented my papers on 1.Seizure related injuries in rural epileptic women from in southern India in the World Congress of Neurology (WCN) 2001 London. 2.Iatrogenic Seizures – A clinical study from southern India in WCN 2001London.3.Circardian onset of stroke in young rural southern Indian population in WCN 2005Sydney 4.Study of psychogenic non epileptic Seizure in southern Indian rural population at WCN 2009 at Bangkok in Thailand. 5.Diffusion MR imaging in status epileptics – Reversibility a study from southern India at WCN 2015 Santiago Chile. All this above Presentation are Published in journal of Neurological science in above in that years as abstract. My research works was accepted by the International League Against Epilepsy and I have presented the paper on Cerebral calcification and epilepsy in rural population at 25thInternational Epilepsy Congress(IEC) 2003 Lisbon Portugal and a paper on southern Indian study on Iatrogenic seizure in 26th IEC 2005 Paris. Both were published as abstract in that year Epilepsia Journal. I have also presented my neurological research work in IANCON, and Neurocon.I have grant from Government of Tamilnadu state research committee to do the research work oncircadian rythem and stroke in southern Indian rural population for one year in 2004.I am a guide for Neurology research work with EEG & fMRI at Department of instrumentation and control. Engineering at National institute of Technology Trichy for PhD scholar from 2013 to 2016.
4.Please outline your contribution to the Indian Academy of Neurology:(Maximum 150 words)
I am a Life member in IAN since 1999 (L M 431).Served in IAN as a National Executive Committee member (2002 – 2009). I was appointed by IAN as organising Secretary to conduct the 2010IANCON for first thetime in 2nd tier city in Trichy As per IAN Instruction I have organised a preconference workshop at during IANCON 2010at Trichy. I am also served as member in the organising committee of IANCON - 2010Madurai and IANCON 2003 VIZAK and IANCON 2004 Nagpur .I have taken part in all IAN instructed Indian National Brain week activities, worldBrain day activities and other Neurological awareness activities.I have contributed articles for Reviews in Neurology on Myasthenic syndrome and on cerebral malaria in 2000 IANCON, and an Hypertension management in stroke in 2003 IANCON.I have chaired sessions and presented papers in IANCON many times. I have Published two Review articles on epilepsy in elderly and published papers in Annales of Indian academy of Neurology.I have undergone specialised training in Epilepsy as an IAN Sponsored candidate for 3 months at University College of London Queen's squire Neurology hospital in 2001IAN helped me to create an award for the Basic science research works with my contribution of Rupees 20 Lakhs to IAN in 2018.I am also served as Tamilnadu Pondicherry Association of Neurologist as vice-president,President Elect and as President for the year 2017 -18 and Now I am The past president of TAN.
5.Please outline your other significant contribution: (Maximum 150 words)
Prof Dr. Aleem has created and established the department of neurology at KAPV GOVT medical college and MGM GOVT hospital Trichy. He had a role in starting the DM Neurology higher specialty. Course at Thirunelveli Govt medical college in 2007. He has published 11 books in regional language on Neurology topics to create awareness among people. He is the examiner in the Tamilnadu Dr. MGR medical University. At present he is the president for Trichy Neuro club and Secretary for Neurologist association of Tiruchirappalli. He is the founder of NAT at Trichy 2017.He is a also instrumental in bringing the International Epilepsy Day by ILAE/IBE in 2015.Prof Dr. M.A. Aleem is conferred with best doctor award in the field of neurology by the Tamilnadu Dr. MGR Medical University in 2012.He had junior travelling fellowship award from WFN to attend WCN 2001 at London. He had congress attendee award from ILAE to attend 25th IEC at Lisbon. He had travelling bursary award from ILAE to attend 6th AOEC at Malaysia in 2006. He had commendation certificate from Trichy District collector for this Neurological Health care services for the year. 2005, 2006, 2014 – 2015, 2015 – 2016, 2016 – 2017.Prof Dr. Aleem had Republic day Best Doctor award for his contribution to rural Neurological awareness activity from Trichy collector in 2010. He had best administrator award from the Trichy district collect in 2013.He also had Dr. Banumathy Muruganathan award for the excellence in medical publication in Tamil by Tamilnadu IMA in 2008.He was nominated as Epilepsy purple day Ambassador in 2012 by EANS Newyork.He was nominated as Trichy district welfare fund committee life member by district collector and Truchy DWFC committee from 2017. He is also an advisor to phd students at NITT Trichy in the Instrumentation Engineering department.Dr Aleem was awarded 1st prize for his suggestions of Trichy SMART CITY by the Tiruchirappalli city Corporation in 2015Dr Aleem was awarded for his our Ptime Minister Modi ' s SWACHH BHARAT activities by Tiruchirappalli district collector in 2017.He is awarded with KALAM Award for Quality of life improvement by South Zone Board if Continuing Education Ozone on 18.11.2018.He has the research experience of more than 20 years in his carrier.ProfDr.M.A.Aleem has the Appointed as Emeritus Professor From Trichy Neurology Field at the Tamilnadu Dr. M.G.R. Medical University in 2018.Dr.Aleem is appointed as Trustee to age old Natharvali Dargah by Wakf Board of Government of Tamilnadu India for three years from 2.11.2018Dr M.A.Aleem 1st Neurologist appointed as Advisory Committee Member for the Tiruchirappalli International Airport by Airport Authority of India Director Tiruchirappalli International Airport on 10.12.2018.Dr. M.A.Aleem first Neurologist Trichy Tamilnadu is Nominated as Brand Ambassador for Swachh Bharat Mission by The Tiruchirappalli City Corporation of Goverment of Tamilnadu India at 70th Republic day on 26.1.2019
Wednesday, December 23, 2020
SARS-CoV-2 Variant (COVID-19 Variant ?COVID-20v1 ) WHO Guidance - M.A.Aleem Neurologist #Trichy #Tamilnadu #India
SARS-CoV-2 Variant
(COVID-19 Variant)
On 14 December 2020, authorities of the United Kingdom (UK) reported to WHO that a new SARS-CoV-2 (COVID-19) variant was identified through viral genomic sequencing.
This variant is referred to as SARS-CoV-2 VUI 202012/01 (Variant Under Investigation, year 2020, month 12, variant 01).
Initial analysis indicates that the variant may spread more readily between people. Investigations are ongoing to determine if this variant is associated with any changes in the severity of symptoms, antibody response or vaccine efficacy.
A total of 1108 cases infected with SARS-CoV-2 VUI 202012/01 have been detected in the UK as of 13 December 2020.
A total of 1108 cases infected with SARS-CoV-2 VUI 202012/01 have been detected in the UK as of 13 December 2020.
The variant was picked up as part of an epidemiological and virological investigation initiated earlier in December 2020 following an unexpected rise in COVID-19 cases in South East England. It was characterized by a more than three-fold increase in the 14-day case notification rate from epidemiological week 41 to week 50 (5 October to 13 December 2020).
On average, between 5 - 10% of all SARS-CoV-2 viruses have routinely been sequenced in the UK and 4% routinely sequenced in South East England since the beginning of the pandemic.
From 5 October to 13 December, over 50% of isolates were identified as the variant strain in South East England. Retrospective analysis traced the first identified variant to Kent, South East England, on 20 September 2020, which was followed by a rapid increase of the same variant identified later in November. Most COVID-19 cases from whom this variant has been identified have occurred in people under 60 years of age.
The variant is defined by the presence of a range of 14 mutations resulting in amino acid changes and three deletions. Some of these mutations may influence the transmissibility of the virus in humans:
One of the mutations identified (N501Y) is altering an amino acid within the six key residues in the receptor binding domain (RBD). According to the Global Initiative on Sharing Avian Influenza Data (GISAID) database, this same receptor binding domain mutation (N501Y) has been independently reported in several countries including South Africa (n=45) and Australia (n=37). Sequence analysis revealed that N501Y mutation of the virus reported in the UK and South Africa originated separately.
The variant is defined by the presence of a range of 14 mutations resulting in amino acid changes and three deletions. Some of these mutations may influence the transmissibility of the virus in humans:
One of the mutations identified (N501Y) is altering an amino acid within the six key residues in the receptor binding domain (RBD). According to the Global Initiative on Sharing Avian Influenza Data (GISAID) database, this same receptor binding domain mutation (N501Y) has been independently reported in several countries including South Africa (n=45) and Australia (n=37). Sequence analysis revealed that N501Y mutation of the virus reported in the UK and South Africa originated separately.
Another mutation of biological significance, P681H, has been found in the RBD.
Finally, the deletion at position 69/70 has been found to affect the performance of some diagnostic PCR assays that use an S gene target. Most PCR assays worldwide use multiple targets and therefore the impact of the variant on diagnostics is not anticipated to be significant.
The new VUI-202012/01 variant has been identified in several countries including Australia, Denmark, Italy, Iceland and the Netherlands.
Preliminary reports by the UK are that this variant is more transmissible than previous circulating viruses, with an estimated increase of between 40% and 70% in transmissibility (adding 0.4 to the basic reproduction number R0, bringing it to a range of 1.5 to 1.7).
Laboratory studies are ongoing to determine whether these variant viruses have different biological properties or alter vaccine efficacy. There is not enough information at present to determine if this variant is associated with any change in severity of clinical disease, antibody response or vaccine efficacy.
Public health response
Public health response
The authorities in the UK are conducting epidemiological and virological investigations to further assess the transmissibility, infection-severity, risk of reinfection and antibody response of this new variant. As one of the mutations (N501Y) is in the receptor binding domain, the authorities are urgently investigating the neutralization activity of sera from recovered and vaccinated patients against this variant to determine if there is any impact on vaccine performance.
Genomic data of this variant has been uploaded to GISAID by the authorities of the UK and genomic surveillance of the virus continues across the country to monitor the situation.
On 19 December 2020, authorities in the UK announced that affected areas would be subject to Tier 4 restrictions including reduced social gatherings, tighter movement restrictions, requests to work from home wherever possible, and closures of non-essential businesses.
WHO risk assessment
All viruses, including SARS-CoV-2, change over time, but most of these mutations or changes do not have a direct benefit to the virus or may even be detrimental to its propagation. Further laboratory investigations are required to more fully understand the impact of specific mutation on viral properties and the effectiveness of diagnostics, therapeutics and vaccines. These investigations are complex and require time and collaboration amongst different research groups.
The sharing of full genome sequences is facilitating detailed analyses by partners. The WHO SARS-CoV-2 Virus Evolution Working Group is working with colleagues from the UK to better understand the available results and support further studies.
Further epidemiological and laboratory-based studies are rapidly required to understand the implications of these viruses in terms of available SARS-CoV-2 clinical presentation, diagnosis, treatment and vaccine development.
WHO advice
The preliminary findings by the UK signal the broader issue of SARS-CoV-2 virus mutations, and WHO underscores the importance of prompt sharing of epidemiological, virological and full genome sequence information with other countries and research teams, including through open-source platforms such as GISAID and others.
WHO advises that further epidemiological and virological studies be conducted to understand the specific mutations described by the UK and other countries to further investigate any changes in the function of the virus in terms of infectivity and pathogenicity. WHO advises all countries to increase the routine sequencing of SARS-CoV-2 viruses where possible, and sharing of sequence data internationally, in particular, to report if the same mutations of concern are found.
WHO would like to draw attention to the concern about the reported loss of performance of PCR assays that target the spike (S) gene of the virus. Laboratories using commercial PCR kits for which the targeted viral genes are not clearly identified in the manufacturer’s instructions are advised to contact the manufacturer for more information. Laboratories using in-house PCR assays that target the S gene of the virus should also be aware of this potential issue. In order to limit the impact on the detection capacities in the countries, an approach using different assays in parallel or multiplex assays targeting different viral genes is also recommended to allow the detection of potential arising variants.
All countries need to assess their level of local transmission and apply appropriate prevention and control activities including adapting public health and social measures as per WHO guidance.
It is important to remind communities and health workers of the basic principles to reduce the general risk of transmission of acute respiratory infections:
Avoiding close contact with people suffering from acute respiratory infections;
Frequent hand-washing, especially after direct contact with ill people or their environment;
People with symptoms of acute respiratory infection should practice cough etiquette (maintain distance, cover coughs and sneezes with disposable tissues or clothing, and wash hands);
Within healthcare facilities, enhance standard infection prevention and control practices in hospitals, especially in emergency departments; and
Wearing masks where appropriate and ensuring good ventilation.
WHO recommends the health measures as listed above for all travelers, including to and from the UK. In case of symptoms suggestive of acute respiratory illness either during or after travel, travelers are encouraged to seek medical attention and share their travel history with their health care provider. Health authorities should work with travel, transport, and tourism sectors to provide travelers with information to reduce the general risk of acute respiratory infections, via travel health clinics, travel agencies, conveyance operators, and at points of entry.
In line with the advice provided by the Emergency Committee on COVID-19 at its most recent meeting, WHO recommends that States Parties should regularly re-consider measures applied to international travel in compliance with Article 43 of the IHR (2005) and continue to provide information and rationale to WHO on measures that significantly interfere with international traffic. Countries should also ensure that measures affecting international traffic are risk-based, evidence-based, coherent, proportionate and time limited.
WHO has recently published an interim guidance – "Considerations for implementing a risk-based approach to international travel in the context of COVID-19", to provide countries with a risk based approach to decision-making process for calibrating travel related risk mitigation measures in the context of international travel, aiming at reducing travel-associated exportation, importation and onward transmission of SARS-CoV-2 while avoiding unnecessary interference with international traffic.
WHO recommends that countries take a risk-based approach. National authorities are encouraged to publish their risk assessment methodology and the list of departure countries to which restrictions apply; and these should be updated regularly. In all circumstances, essential travel (e.g. emergency responders; providers of public health technical support; critical personnel in transport and security sector such as seafarers; repatriations; and cargo transport for essential supplies such as food, medicines, and fuel) identified by countries should always be prioritized and facilitated.
As of now on 23.12 20 India has not reported any such COVID-19 variant in any states. India has taken taken various preventive steps including cancellation of flight from UK till December 31st, 2020 to check the spread of new COVID-19 Variant in India.
Tuesday, December 22, 2020
Monday, December 21, 2020
Sunday, December 20, 2020
coronawarriors Award to #Trichy Doctors News in Trichy NTrichy.com on 21.12.2020- M.A.Aleem Neurologist #Trichy #Tamilnadu #India
#COVID19India
#coronawarriors Award to #Trichy Doctors News in Trichy NTrichy.com on 21.12.2020- M.A.Aleem Neurologist #Trichy #Tamilnadu #India
à®…à®°ிà®®ா சங்கத்தின் சாà®°்பில் அரசு மருத்துவர்களுக்கு covid-19Warriors பட்டம் கேடயம் ! https://ntrichy.com/2020/12/20/covid-19warriors-degree-shield-for-government-doctors-on-behalf-of-arima-association/
#COVID19India #coronawarriors Award to #Trichy Doctors News in Trichy NTrichy.com on 21.12.2020- M.A.Aleem Neurologist #Trichy #Tamilnadu #Indiaà®…à®°ிà®®ா சங்கத்தின் சாà®°்பில் அரசு மருத்துவர்களுக்கு covid-19Warriors பட்டம் கேடயம் ! https://ntrichy.com/2020/12/20/covid-19warriors-degree-shield-for-government-doctors-on-behalf-of-arima-association/
#coronawarriors Award to #Trichy Doctors News in Trichy the Hindu @the_hindu on 21.12.2020- M.A.Aleem Neurologist #Trichy #Tamilnadu #IndiaCOVID-19 warriors feted https://www.thehindu.com/todays-paper/tp-national/tp-tamilnadu/covid-19-warriors-feted/article33380915.eceTAMIL NADUCOVID-19 warriors fetedSPECIAL CORRESPONDENTTIRUCHI, DECEMBER 21, 2020 00:00 ISTUPDATED: DECEMBER 21, 2020 04:09 ISTLions Club of Tiruchirappalli, Rockfort Inspire, on Saturday, held a function to honour medical practitioners for their service to control COVID-19 virus.K. Vanitha, Dean, K.A.P. Viswanatham Medical College; M.A. Aleem, former Vice Principal; and S. Kamaraj, District Siddha Medical Officer, Tiruchi, were given COVID-19 warrior awards.M. Natarajan, Charter President; S. Murugesan, Secretary of the club, and others participated in the function.
Lions Clubs International Tiruchirappalli Rockfort Inspire on 19.12.2020 Awarded "COVID-19 Warrior Award" to Dr.M.A.Aleem Former Vice Principal HOD and Professor of Neurology KAPV Government Medical College Trichy Tamilnadu India in recognition of his COVID-19 related Awareness Activities and Free Tele-consultation during Lockdown Period during the Current COVID-19 Pandemic. Director "Savai" Govindaraj presented the award in the presence of Charter President Ln. M.Natarajan , Secretary Ln Lr. S. Murugasan and Poet Nandalala and KAPVGMC Dean M. Vanitha and Siddha District Officer S.Kamaraj.
Saturday, December 19, 2020
Lions Clubs International Tiruchirappalli Rockfort Inspire on 19.12.2020 Awarded "COVID-19 Warrior Award" to Dr.M.A.Aleem Former Vice Principal HOD and Professor of Neurology KAPV Government Medical College Trichy Tamilnadu India in recognition of his COVID-19 related Awareness Activities and Free Tele-consultation during Lockdown Period during the Current COVID-19 Pandemic
Friday, December 18, 2020
India has lower COVID-19 Deaths - M.A.Aleem BMJ 2020;371:m4728BMJ 2020;371:m4728
BMJ British Medical Journal
Feature
Christmas 2020: House of God
The covid-19 yearbook: world leaders edition
BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4728 (Published 16 December 2020)
Cite this as: BMJ 2020;371:m4728
Rapid response
Re: The covid-19 yearbook: world leaders edition
Dear Editor
India has lower COVID-19 Deaths
With the leadership of our Prime Minister Modi, in the 51st week of the COVID-19 Pandemic, India has a lower COVID-19 related death rate of 1.45% and a recovery rate of 95.35%.
The daily COVID-19 cases numbers have come down to around 18k.
With masks, social distancing and personal hygiene and without any vaccines, India has achieved and continues saving lives and livelihoods with Our PM Modi's leadership.
So far Two COVID-19 vaccines are in use in the world in the 51st week of the COVID-19 Pandemic
The FDA has approved two USA vaccines for COVID-19.
The first one is the Pfizer vaccine, which has 95% efficacy with two doses in a 21 day interval. This should be stored at -60°to -40°c. This vaccine is indicated in the age group of 16 and above.
The second vaccine is Moderna, which has 94.5% efficacy in two doses in a 28 day interval. This should be stored at -25° to -15°c. This vaccine is advised in the age group of 18 and above.
Pfizer and Moderna are mRNA vaccines. Messenger RNA molecules of the virus code for parts of the target pathogen that are recognised by our immune system (antigens). Inside our body's cells, the RNA molecules are converted into antigens, which are then detected by our immune cells to produce antibodies.
With and without vaccines, the wearing of masks, washing of hands and keeping of social distancing are the corner stones to beat the COVID-19 during this Pandemic.
Wish you all COVID-19 free Happy Christmas 2020 and a Happy New year 2021.
Competing interests: No competing interests
18 December 2020
M.A. Aleem
Emeritus Professor of Neurology * Visiting Specialist in Neurology ** Consultant Neurologist ***
The Tamilnadu Dr.M.G.R. Medical University * Dhanalakshami Srinivasan Medical College ** ABC Hospital ***
Chennai 600032* Perambalure 621212** Trichy 620018*** Tamilnadu India
@drmaaleem
Monday, December 14, 2020
COVID-19: India continues saving lives and livelihoods - M.A.Aleem BMJ 2020;371:m4764BMJ 2020;371:m4764
Bmj British Medical Journal
Editor's Choice
Covid-19: Transparency and communication are key
BMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4764 (Published 10 December 2020)
Cite this as: BMJ 2020;371:m4764
Rapid response
Re: Covid-19: Transparency and communication are key
Dear Editor
COVID-19: India continues saving lives and livelihoods
At present there are about 0.9% of the world population is infected with COVID-19 in the 50th week of the current COVID-19 Pandemic.
As of on 11.12.2020 there are more than
70.8 million (70,848,102) confirmed COVID-19 cases with over 1.5 million (1,591,266) deaths in the 218 countries (Samoa is the 218th country added on 19.11
20 )and territories in all continents and in 2 International conveyances in the world.
The global total COVID-19 cases has crossed 70.8 million mark
and it has registered a global ever highest single day spike of over 6.7 lakh ( 676,806) cases with the single day highest number of deaths of 12,625 cases on 10.12.20.
Among the currently COVID-19 infected people , mildly infected people has been raised to 99.5% and the critically affected people has come down to 0.5% on 9.12.20 during this Pandemic .
USA has registered a higher single day spike of over 2 lakh (217,779) COVID-19 cases and the total cases has crossed 16 million mark (16,039,393) with over 2.9 lakh (299,692) deaths ( single day deaths of 2974) on 10.12.20
Cases and death rate in India including in the state of Tamilnadu and in my own district of Trichy are declining .
India is in the second place after USA in the list of global single day spike of COVID-19 cases with the number of over 34k (34,666) with the single day death of 487 cases and the totol has crossed 9.7 million mark (9,796,992)
on 10.12.2020 during this Pandemic.
In India the recovered cases were over 9.2 million mark (9,290,188) in India on 10.12.2020
India continues saving lives and livelihoods – recording more COVID-19 recoveries while lifting restrictions.
A decrease in new weekly COVID-19 cases is reported in India in the 50th week of the Pandemic.
Competing interests: No competing interests
12 December 2020
M.A. Aleem
Emeritus Professor of Neurology * Visiting Specialist in Neurology ** Consultant Neurologist ***
The Tamilnadu Dr.M.G.R. Medical University * Dhanalakshami Srinivasan Medical College ** ABC Hospital ***
Chennai 600032* Perambalure 621212** Trichy 620018*** Tamilnadu India
@drmaaleem
Sunday, December 13, 2020
Saturday, December 12, 2020
Wednesday, December 9, 2020
Tuesday, December 8, 2020
Monday, December 7, 2020
Declining #COVID19 cases in #Trichy District after #Diwali2020 is the "Combined Efforts " of all districts officials by M.A.Aleem Neurologist #Trichy #Tamilnadu #India in the Readers Mail Column of Tiruchi the Hindu @the_hindu on 7.12.2020.Readers Mail https://www.thehindu.com/todays-paper/tp-national/tp-tamilnadu/readers-mail/article33266515.ece
Sunday, December 6, 2020
Declining #COVID19 cases in #Trichy District after #Diwali2020 is the "Combined Efforts " of all districts officials by M.A.Aleem Neurologist #Trichy #Tamilnadu #India in the Readers Mail Column of Tiruchi the Hindu @the_hindu on 7.12.2020.Readers Mail https://www.thehindu.com/todays-paper/tp-national/tp-tamilnadu/readers-mail/article33266515.ece
COVID-19 situations in the 1st day of 50th of COVID-19 Pandemic
The global total COVID-19 cases has crossed 67.3 million mark (67,377,122)
and it has registered a global higher single day spike of over 5.3 lakh ( 534,677) cases with the single day higher number of deaths of 7,534 cases on 6.12.20
USA has registered a higher single day spike of over 1.7 lakh number of 173,861 COVID-19 cases and the total cases has crossed 15.1 million mark (15,159,529) with over 2.8 lakh (288,906) deaths ( single day deaths of higher 1076) on 6.12.20
Cases in India and in Tamilnadu Trichy are declining and India is in the second place after USA in the list of global single day spike of COVID-19 cases with the number of over 32k (32,272) with the single day death of 374 cases and the totol has crossed 9.6 million mark (9,676,801)
on 6.12.2020 during this Pandemic. The recovered cases were over 9.1 million mark (9,138,171) in India on 6.12.2020
As of on 7.12. 20 in 218 countries (Samoa is the 218th country added on 19.11
20 )and territories in all continents and in 2 International conveyances over 67.3 Million mark (67,385,185) with India over 9.6 Million mark (9,676,801) and 790,240
in the State of Tamilnadu , and in Trichy 13,590 cases were reported with COVID-19 infection .Recovered cases were over 46.5 Million mark (46,578,897) and over 1.5 million (1,541,638) deaths in world which include 140,590 in India and 11,793 in Tamilnadu and 172 at Trichy has been recorded as of 7.12.2020.
M.A.Aleem Neurologist Trichy Tamilnadu India
Wednesday, December 2, 2020
#PostDiwalli #COVID19 Situation at #Trichy District article by C Jaisankar @jaisank70905230In the Hindu @the_hindu #Trichy- M.A.Aleem Neurologist #Tamilnadu #India Post-Deepavali, no significant spike in fresh cases in Tiruchi: Collector - The Hindu - https://www.thehindu.com/news/cities/Tiruchirapalli/post-deepavali-no-significant-spike-in-fresh-cases-in-tiruchi-collector/article33225664.ece
The Hindu Trichy 2.12.2020
Post-Deepavali, no significant spike in fresh cases in Tiruchi: Collector
Post-Deepavali, there has been no significant spike in fresh cases of COVID-19 in Tiruchi district.
Though the cases were on a declining trend in the district for the last three to four weeks, it was feared that the number of fresh cases may go up post-Deepavali due to festivities, mutual visits of people and large-scale rush of shoppers on commercial streets of the city for festival purchase
However, statistics of the Health Department shows that no area in the district has registered abnormal rise in fresh case of COVID-19 since November 14. Fresh cases are on the steady decline in spite of testing for a high number of samples.
The COVID-19 testing laboratory at K.A.P. Viswanatham Medical College receives samples from about 80 points of sample collections daily including Primary Health Centres, Urban Primary Health Centres, fever outreach camps, surveillance camps and mobile camps.
On an average, the lab receives 1,800 samples a day. However, the daily count of fresh cases hovers around 20 to 30. No cluster of fresh cases have been noticed. A total of 52,816 samples were tested in November. Of them, 916 patients tested positive.
“We have not come across any noticeable spike in any part of the district after Deepavali. Although the fight against COVID-19 is far from over, it is a positive development”” said Collector S. Sivarasu.
As on Monday, 160 patients are under treatment including those of home isolation. Out of 13,421 total cases, 13,089 patients have been discharged from hospitals in the district.
“It has been noted that the viral infection has come down to a great extent. The arrival of newly infected people from other districts has also come down. However, it is too early to come to a conclusion on the spread of COVID-19,” said A. Aravind Kumar, District Epidemiologist.
“There were days when dedicated beds for COVID-19 in private hospitals were overflowing. Now, more than 75% of the beds are vacant. It is a good sign in controlling the virus”” says M.A. Aleem, a city-based neurologist.
There can be no complacency. The next three tofour weeks are crucial. Hence, health, civic and rural development officials have been asked to ramp up surveillance, Mr. Sivarasu said.
#PostDiwalli #COVID19 Situation at #Trichy District article by C Jaisankar @jaisank70905230In the Hindu @the_hindu #Trichy- M.A.Aleem Neurologist #Tamilnadu #India Post-Deepavali, no significant spike in fresh cases in Tiruchi: Collector - The Hindu - https://www.thehindu.com/news/cities/Tiruchirapalli/post-deepavali-no-significant-spike-in-fresh-cases-in-tiruchi-collector/article33225664.ece
Subscribe to:
Posts (Atom)